Advertisement


Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Opening Session Panel Discussion

Advertisement

Advertisement



Dec
09
Today In Oncology
Elacestrant May Improve Outcomes for Postmenopausal Patients With Progressive ER-Positive HER2-Negative Metastatic Breast Cancer (1)
PALLAS Trial Addition of Adjuvant Palbociclib to Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
Telemedicine Use Among U.S. Patients With Newly Diagnosed Cancer Impact of Socioeconomic Status
COVID-19 Infection After SARS–CoV-2 Messenger RNA Vaccination in Patients With Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside